Incidence, prevalence, and management of opioid bowel dysfunction.
暂无分享,去创建一个
[1] B. Krevsky,et al. Role of opiate receptors in the regulation of colonic transit. , 1988, Gastroenterology.
[2] M. Petersen,et al. Development of a protocol to prevent opioid-induced constipation in patients with cancer: a research utilization project. , 2000, Clinical journal of oncology nursing.
[3] Spencer S. Liu,et al. ADL 8‐2698, a trans‐3,4‐dimethyl‐4‐ (3‐hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia , 2001, Clinical pharmacology and therapeutics.
[4] N. Sykes. A volunteer model for the comparison of laxatives in opioid-related constipation. , 1996, Journal of pain and symptom management.
[5] T. Reisine. Opioid analgesics and antagonists , 1996 .
[6] L. Manara,et al. The central and peripheral influences of opioids on gastrointestinal propulsion. , 1985, Annual review of pharmacology and toxicology.
[7] A. De Luca,et al. Insights into opioid action in the intestinal tract. , 1996, Pharmacology & therapeutics.
[8] M. Roizen,et al. Methylnaltrexone prevents morphine‐induced delay in oral‐cecal transit time without affecting analgesia: A double‐blind randomized placebo‐controlled trial , 1996, Clinical pharmacology and therapeutics.
[9] Knowles,et al. Slow transit constipation: a model of human gut dysmotility. Review of possible aetiologies , 2000, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[10] M. Clasen,et al. Managing pain in the dying patient. , 2000, American family physician.
[11] S. Ahmedzai,et al. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. , 1997, Journal of pain and symptom management.
[12] S. Kaasa,et al. Effects on cancer patients' health-related quality of life after the start of morphine therapy. , 2000, Journal of pain and symptom management.
[13] S. Ahmedzai,et al. Transdermal fentanyl versussustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life , 1997 .
[14] V. Hruby,et al. Peptide opioid antagonist separates peripheral and central opioid antitransit effects. , 1987, The Journal of pharmacology and experimental therapeutics.
[15] L. Cheskin,et al. Constipation in the elderly. , 1998, American family physician.
[16] C. Yuan,et al. Effects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guinea-pig ileum and human intestine. , 1995, European journal of pharmacology.
[17] J. Jaffe,et al. Assessment of nalmefene glucuronide as a selective gut opioid antagonist. , 1995, Drug and alcohol dependence.
[18] M. Roizen,et al. Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study , 1999, PAIN®.
[19] H. Merskey,et al. Randomised trial of oral morphine for chronic non-cancer pain , 1996, The Lancet.
[20] G. Hanks,et al. Morphine, constipation and performance status in advanced cancer patients , 1999, Palliative medicine.
[21] F. Fulfaro,et al. The impact of home palliative care on symptoms in advanced cancer patients , 2000, Supportive Care in Cancer.
[22] P. Bass,et al. Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. , 1982, European journal of pharmacology.
[23] S. Grond,et al. Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic. , 1994, Journal of pain and symptom management.
[24] M. Roizen,et al. Effects of enteric‐coated methylnaltrexone in preventing opioid‐induced delay in oral‐cecal transit time , 2000, Clinical pharmacology and therapeutics.
[25] P. Glare,et al. Unrecognized constipation in patients with advanced cancer: a recipe for therapeutic disaster. , 1992, Journal of pain and symptom management.
[26] E. Bruera,et al. Topics in palliative care , 1997 .
[27] N. Sykes,et al. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer , 1996, Palliative medicine.
[28] M. Roizen,et al. The safety and efficacy of oral methylnaltrexone in preventing morphine‐induced delay in oral‐cecal transit time , 1997, Clinical pharmacology and therapeutics.
[29] S. Moncada,et al. Endogenous nitric oxide modulates morphine-induced constipation. , 1991, Biochemical and biophysical research communications.
[30] P. Pandhi,et al. Effect of acute and chronic administration of L-arginine on morphine induced inhibition of gastrointestinal motility. , 2000, Indian journal of physiology and pharmacology.
[31] P. Ferretti,et al. Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid sites. , 1986, The Journal of pharmacology and experimental therapeutics.
[32] E. Bruera,et al. Constipation in advanced cancer patients , 1998, Supportive Care in Cancer.
[33] J. Foss,et al. Oral methylnaltrexone for opioid-induced constipation. , 2000, JAMA.
[34] N. Sykes. The relationship between opioid use and laxative use in terminally ill cancer patients , 1998, Palliative medicine.
[35] S. Kaasa,et al. Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation. , 2000, Acta anaesthesiologica Scandinavica.
[36] D. Walsh,et al. Prevention of opioid side effects. , 1990, Journal of pain and symptom management.
[37] M. Roizen,et al. Gut Motility and Transit Changes in Patients Receiving Long‐Term Methadone Maintenance , 1998, Journal of clinical pharmacology.
[38] K. Reinhart,et al. Oral naloxone reverses opioid-associated constipation , 2000, Pain.
[39] Felicia A. Dello Buono,et al. Opioid Antagonists in the Treatment of Opioid-Induced Constipation and Pruritus , 2001, The Annals of pharmacotherapy.
[40] R. Portenoy,et al. Treatment of opioid-induced constipation with oral naloxone: a pilot study. , 1993, Clinical pharmacology and therapeutics.
[41] L. Goodman,et al. The Pharmacological Basis of Therapeutics , 1941 .
[42] M. Roizen,et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. , 2000, JAMA.
[43] M. Levy. Pharmacologic treatment of cancer pain. , 1996, The New England journal of medicine.